title: Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
authors.affiliation: Department of Genitourinary Medical Oncology.
authors.forename: S L
authors.initials: SL
authors.lastname: Richey
authors.affiliation: Department of Urology, MD Anderson Cancer Center, Houston, USA.
authors.forename: S H
authors.initials: SH
authors.lastname: Culp
authors.affiliation: Department of Genitourinary Medical Oncology.
authors.forename: E
authors.initials: E
authors.lastname: Jonasch
authors.affiliation: Department of Urology, MD Anderson Cancer Center, Houston, USA.
authors.forename: S F
authors.initials: SF
authors.lastname: Matin
authors.affiliation: Department of Urology, MD Anderson Cancer Center, Houston, USA.
authors.forename: C G
authors.initials: CG
authors.lastname: Wood
authors.affiliation: Department of Genitourinary Medical Oncology. Electronic address: ntannir@mdanderson.org.
authors.forename: N M
authors.initials: NM
authors.lastname: Tannir
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies